04 Mar 2014, BioSpectrum Bureau , BioSpectrum
Singapore: AB Sciex, a global leader in analytical technologies, has launched a breakthrough technology solution called CESI-MS, to help biopharmaceutical scientists to accurately predict efficacy, reduce the time to market for new therapeutics and proactively detect potential issues before they lead to costly product recalls.
CESI marks a combination of capillary electrophoresis (CE) and electrospray ionization (ESI) technologies to create an integrated workflow solution unlike anything else on the market. CESI-MS workflow includes ultra-low-flow separation and ESI module for biologics, along with a high-performance, high-resolution, accurate mass instrument that is ideal for biopharmaceutical development, which is the fastest-growing segment of the drug discovery and development sector.
CESI 8000 System for Biologics Characterization is an innovative, high-performance separation-electrospray ionization system for mass spectrometry (MS). This new front-end CESI technology from the company's SCIEX Separations business can be integrated with the well-established AB Sciex TripleTOF 5600+ mass spectrometry system into a seamless solution, for example, to give biopharmaceutical scientists the ability to advance therapeutics discovery, research and development through the life cycle of the product.
"AB SCIEX is partnering with biopharmaceutical companies around the world to advance biologics," said Mr. Jeff Chapman, Director, CE Business within SCIEX Separations, a part of AB Sciex. "With CESI-MS, we are establishing a new benchmark of improved system performance for routine biologics analysis in a way that allows CESI to be easily integrated into existing workflows in biopharmaceutical laboratories. This is innovation delivered to help save more lives and address the unmet needs of our customers in biopharma."